A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

@article{Cascinu2000ACO,
  title={A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).},
  author={S. Cascinu and L. Frontini and R. Labianca and V. Catalano and S. Barni and C. Graiff and G. Picone and E. Farinati and S. Zonato and M. A. Pessi and C. Curti and G. Catalano},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 10},
  pages={
          1309-11
        }
}
BACKGROUND Laboratory evidences suggest the possibility that an infusion rate of 10 mg/m2/min may be more effective than the standard 30-min infusion of Gemcitabine (GEM). PATIENTS AND METHODS Thirty-four patients with histologically verified locally unresectable and/or metastatic pancreatic carcinoma received GEM at the dose of 1,500 mg/m2 with an infusion rate of 10 mg/m2/min, associated to 5-fluorouracil (5-FU) at the dose of 600 mg/m2. Both drugs were administered weekly for two… Expand
38 Citations
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)
  • 3
Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
  • 31
Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
  • 9
  • PDF
A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.
  • 12
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
  • 171
Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.
  • H. Hochster
  • Medicine
  • International journal of radiation oncology, biology, physics
  • 2003
  • 23
Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic Cancer
  • Jeeyun Lee, Joon Oh Park, +13 authors Keunchil Park
  • Medicine
  • Oncology
  • 2004
  • 20
...
1
2
3
4
...

References

SHOWING 1-10 OF 16 REFERENCES
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
  • 178
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
  • 92
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
  • 5,082
  • PDF
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
  • 30
No standard treatment is available for advanced pancreatic cancer.
  • 89
Optimal two-stage designs for phase II clinical trials.
  • R. Simon
  • Medicine
  • Controlled clinical trials
  • 1989
  • 3,009
  • PDF
...
1
2
...